title: [Clinical characteristics and prognosis of 35 patients with therapy-related hematological neoplasms].
abstract: OBJECTIVE
  To investigate the morbidity, treatment outcomes and prognosis of 35 therapy-related hematological neoplasms patients.
  
  
  METHODS
  A total of 35 cases of therapy-related hematological neoplasms were examined genetically and immunologically using flow cytometry, karyotype analysis and FISH, and their clinical data were retrospective analyzed and literatures were reviewed.
  
  
  RESULTS
  Among 35 patients, there were 20 cases of therapy-related acute myeloid leukemia (t-AML), 4 cases of therapy-related acute lymphoblastic leukemia (t-ALL), 1 case of acute mixed leukemia, therapy-related non-hodgkin' s lymphoma (t-NHL) in 8 cases and myelodysplastic syndrome (t-MDS) in 2 cases. The median onset of t-HN was 29(16-90) months, the median OS of t-HN was 14(1-60) months, and 3 years of OS was 17.1%. Among therapy-related acute leukemia (t-AL) patients, 40% (10/25) patients had combined complex karyotype, 36% (9/25) patients with MLL gene rearrangement, 12% (3/25) patients with combined AML/ETO fusion gene, 1 case with NPM1 point mutation and 1 case with P16 gene deletion.
  
  
  CONCLUSIONS
  Therapy-related hematological neoplasms had a worse prognosis.
authors.affiliation: Department of Hematology, Nanfang Hospital, Southern Medical University, 510515 Guangzhou, China.
authors.forename: Q S
authors.initials: QS
authors.lastname: Lu
authors.forename: N
authors.initials: N
authors.lastname: Xu
authors.forename: X
authors.initials: X
authors.lastname: Zhou
authors.forename: G X
authors.initials: GX
authors.lastname: Cai
authors.forename: L
authors.initials: L
authors.lastname: Li
authors.forename: Y L
authors.initials: YL
authors.lastname: Li
authors.forename: Z Y
authors.initials: ZY
authors.lastname: Lu
authors.forename: J X
authors.initials: JX
authors.lastname: Huang
authors.forename: Q F
authors.initials: QF
authors.lastname: Liu
authors.forename: X L
authors.initials: XL
authors.lastname: Liu
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D002869:Chromosome Aberrations; D019337:Hematologic Neoplasms / Q000139:chemically induced / Q000175:diagnosis*; D006801:Humans; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced / Q000175:diagnosis; D008228:Lymphoma, Non-Hodgkin / Q000139:chemically induced / Q000175:diagnosis; D009190:Myelodysplastic Syndromes / Q000139:chemically induced / Q000175:diagnosis; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000175:diagnosis*; D000090243:Nucleophosmin; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000139:chemically induced / Q000175:diagnosis; D011379:Prognosis; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; C000716967:NPM1 protein, human; D000090243:Nucleophosmin